| 1.06 0.225 (26.99%) | 02-13 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.51 |
1-year : | 1.77 |
| Resists | First : | 1.29 |
Second : | 1.51 |
| Pivot price | 0.95  |
|||
| Supports | First : | 0.98 |
Second : | 0.79 |
| MAs | MA(5) : | 0.89 |
MA(20) : | 0.99 |
| MA(100) : | 1.06 |
MA(250) : | 0.89 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 27.1 |
D(3) : | 15.2 |
| RSI | RSI(14): 56.5 |
|||
| 52-week | High : | 1.5 | Low : | 0.33 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ONCY ] has closed below upper band by 26.2%. Bollinger Bands are 66.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 16 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.1 - 1.11 | 1.11 - 1.11 |
| Low: | 0.82 - 0.83 | 0.83 - 0.84 |
| Close: | 1.05 - 1.06 | 1.06 - 1.07 |
Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.
Fri, 13 Feb 2026
Oncolytics Biotech (NASDAQ:ONCY) Insider Purchases $25,456.00 in Stock - MarketBeat
Fri, 13 Feb 2026
Patricia Andrews Acquires 35,400 Shares of Oncolytics Biotech (NASDAQ:ONCY) Stock - MarketBeat
Fri, 13 Feb 2026
Oncolytics Biotech (NASDAQ:ONCY) Director Purchases $34,000.00 in Stock - MarketBeat
Fri, 13 Feb 2026
Oncolytics Biotech (NASDAQ:ONCY) CFO Kirk Look Acquires 12,000 Shares - MarketBeat
Thu, 05 Feb 2026
$207B Market Shift: The Race for Fast Track Approval in Oncology - Sahm
Wed, 04 Feb 2026
Colorectal cancer drug shows 2-3x gains, earns FDA Fast Track status - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 108 (M) |
| Shares Float | 104 (M) |
| Held by Insiders | 2.6 (%) |
| Held by Institutions | 2.4 (%) |
| Shares Short | 3,760 (K) |
| Shares Short P.Month | 3,550 (K) |
| EPS | -0.31 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -111.3 % |
| Return on Equity (ttm) | -769.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.33 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -26 (M) |
| Levered Free Cash Flow | -13 (M) |
| PE Ratio | -3.54 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.31 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|